With backing from a petition that is now circulating online, the Friedrich’s Ataxia Research Alliance (FARA) will ask…
Articles by Forest Ray PhD
Larimar Therapeutics completed dosing for its single-ascending dose (SAD) Phase 1 clinical trial of CTI-1601, a modified version of…
The Friedreich’s Ataxia Research Alliance (FARA) has shared a list of three clinical studies and one global registry that…
Lifetime TV‘s October 2 special edition of “Behind the Mystery: Rare and Genetic” focuses on Friedreich’s ataxia…
An initiative called the Friedreich’s Ataxia Accelerator has been launched by the Broad Institute of Massachusetts Institute of Technology…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography…
Team Gleason and CureDuchenne have teamed with Google’s Project Euphonia to make automated speech recognition more accessible…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the…
The Committee for Orphan Medicinal Products (COMP), an arm of the European Medicines Agency (EMA), has…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure…